$SEEL
Seelos Therapeutics Inc Stock $seel

$seel Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000101749118000075 Filed on August 09, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.930M	$2.080M	$2.410M
YoY Change	9.66%	30.0%	26.84%
% of Gross Profit
Research & Development	$769.0K	$162.0K	$240.0K
YoY Change	-60.77%	-80.69%	-60.66%
% of Gross Profit
Depreciation & Amortization			$20.00K
YoY Change			-118.18%
% of Gross Profit
Operating Expenses	$2.703M	$2.237M	$2.650M
YoY Change	-27.26%	-8.36%	5.58%
Operating Profit	-$2.703M	-$2.237M
YoY Change	-27.26%	-8.36%
Interest Expense	$0.00	$0.00	-$50.00K
YoY Change	-100.0%	-100.0%	-102.27%
% of Operating Profit
Other Income/Expense, Net	-$135.0K	-$16.00K	$100.0K
YoY Change	-53.92%	-102.23%
Pretax Income	-$2.840M	-$2.250M	-$2.600M
YoY Change	-29.18%	30.81%	712.5%
Income Tax
% Of Pretax Income
Net Earnings	-$2.838M	-$2.277M	-$2.450M
YoY Change	-25.94%	54.48%	716.67%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.595M	-$2.923M	-$4.804M
COMMON SHARES
Basic Shares Outstanding	23.44M shares	23.44M shares	15.22M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.280M	$6.840M	$6.330M
YoY Change	-37.59%	-12.53%	202.87%
Cash & Equivalents	$5.283M	$6.836M	$6.331M
Short-Term Investments
Other Short-Term Assets	$200.0K	$290.0K	$260.0K
YoY Change	-13.04%	-65.06%	-83.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.481M	$7.130M	$6.592M
YoY Change	-36.91%	-17.56%	81.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.00K	$56.00K	$79.00K
YoY Change	-54.0%	-53.72%	-51.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$37.00K	$36.00K	$35.00K
YoY Change	5.71%	-20.0%	-41.67%
Total Long-Term Assets	$83.00K	$92.00K	$114.0K
YoY Change	-38.52%	-44.58%	-89.31%
TOTAL ASSETS
Total Short-Term Assets	$5.481M	$7.130M	$6.592M
Total Long-Term Assets	$83.00K	$92.00K	$114.0K
Total Assets	$5.564M	$7.222M	$6.706M
YoY Change	-36.94%	-18.07%	42.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$320.0K	$1.050M	$60.00K
YoY Change	23.08%	650.0%	-92.11%
Accrued Expenses	$766.0K	$454.0K	$650.0K
YoY Change	-2.17%	-36.59%	-51.24%
Deferred Revenue	$0.00		$12.00K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.425M	$1.903M	$1.583M
YoY Change	-21.44%	3.2%	-85.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$26.00K	$35.00K	$58.00K
YoY Change	-51.85%	-41.67%	-23.68%
Total Long-Term Liabilities	$26.00K	$35.00K	$58.00K
YoY Change	-51.85%	-41.67%	-23.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.425M	$1.903M	$1.583M
Total Long-Term Liabilities	$26.00K	$35.00K	$58.00K
Total Liabilities	$1.451M	$1.938M	$2.335M
YoY Change	-42.05%	-13.6%	-80.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$323.4M	-$320.5M	-$316.0M
YoY Change	3.14%	3.5%	-0.1%
Common Stock	$327.5M	$325.8M	$320.4M
YoY Change	2.38%	3.02%	3.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.113M	$5.284M	$4.371M
YoY Change
Total Liabilities & Shareholders Equity	$5.564M	$7.222M	$6.706M
YoY Change	-36.94%	-18.07%	42.68%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q4
OPERATING ACTIVITIES
Net Income	-$2.838M	-$2.277M	-$2.450M
YoY Change	-25.94%	54.48%	716.67%
Depreciation, Depletion And Amortization			$20.00K
YoY Change			-118.18%
Cash From Operating Activities	-$540.0K	-$330.0K	-$2.480M
YoY Change	-82.12%	-85.46%	-8.49%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$210.0K
YoY Change
Cash From Investing Activities			$210.0K
YoY Change			2000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	700.0K	500.0K	130.0K
YoY Change	-79.53%	-91.78%	-115.66%
NET CHANGE
Cash From Operating Activities	-540.0K	-330.0K	-2.480M
Cash From Investing Activities			210.0K
Cash From Financing Activities	700.0K	500.0K	130.0K
Net Change In Cash	160.0K	170.0K	-2.140M
YoY Change	-75.38%	-95.81%	-39.38%
FREE CASH FLOW
Cash From Operating Activities	-$540.0K	-$330.0K	-$2.480M
Capital Expenditures			$0.00
Free Cash Flow			-$2.480M
YoY Change			-8.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	apri	Aggregate Liability Limitation Indemnification Claims AggregateLiabilityLimitationIndemnificationClaims	2000000	USD
	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	500000	USD
	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	500000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Carrying Value Of Assets DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodCarryingValueOfAssets	1578000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferred	1186000	USD
	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred After Closing Date DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferredAfterClosingDate	1100000	USD
CY2018Q2	apri	Entity Public Float Primary Public Offerings Of Securities Threshold EntityPublicFloatPrimaryPublicOfferingsOfSecuritiesThreshold	75000000	USD
CY2017Q1	apri	Expected Payments For Transition Services Number Of Quarterly Payments ExpectedPaymentsForTransitionServicesNumberOfQuarterlyPayments	2	payment
	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	-422000	USD
	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	0	USD
	apri	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	3550000	USD
	apri	Noncash Financing Activities Issuance Of Placement Agent Warrants NoncashFinancingActivitiesIssuanceOfPlacementAgentWarrants	176000	USD
	apri	Noncash Financing Activities Issuance Of Placement Agent Warrants NoncashFinancingActivitiesIssuanceOfPlacementAgentWarrants	105000	USD
	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	798000	USD
	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	472000	USD
CY2016Q2	apri	Proceeds From Issuance Of Sale Of Equity Net Of Transaction Costs ProceedsFromIssuanceOfSaleOfEquityNetOfTransactionCosts	9600000	USD
CY2017Q2	apri	Proceeds From Sale Of Product Related Inventory ProceedsFromSaleOfProductRelatedInventory	709000	USD
CY2017Q2	apri	Proceeds From Sale Of Product Related Inventory ProceedsFromSaleOfProductRelatedInventory	700000	USD
CY2018Q2	apri	Public Float Primary Public Offerings Of Securities Percent Of Public Float Eligible To Be Raised If Under Threshold PublicFloatPrimaryPublicOfferingsOfSecuritiesPercentOfPublicFloatEligibleToBeRaisedIfUnderThreshold	0.3333
CY2017Q1	apri	Purchase Agreement Maximum Potential Proceeds From Divestiture PurchaseAgreementMaximumPotentialProceedsFromDivestiture	12700000	USD
CY2017Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	61000	USD
CY2018Q2	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	21000	USD
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0
CY2018Q2	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	9415000	shares
CY2018Q2	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	0.96
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	1.48
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	0.51
CY2017Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.91
CY2018Q2	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.96
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice	19.81
CY2018Q2	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	96500000	USD
	apri	Warrant Liability Reclassified To Stockholders Equity WarrantLiabilityReclassifiedToStockholdersEquity	472000	USD
CY2018Q2	apri	Working Capital WorkingCapital	5200000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23441449	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
	dei	Trading Symbol TradingSymbol	APRI
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	58000	USD
CY2018Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1054000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	56000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	0	USD
CY2017Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	863000	USD
CY2018Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	374000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	650000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	454000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	575000	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	379000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	320343000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	325796000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	556000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	550000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	158000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	287000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	572000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	256000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	556000	USD
CY2017Q4	us-gaap	Assets Assets	6706000	USD
CY2018Q2	us-gaap	Assets Assets	7222000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	6592000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	7130000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2087000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7821000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6331000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6836000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5734000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	505000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	11750000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-114000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-3000	USD
CY2018Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	9415000	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15217231	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23441449	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15217231	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23441449	shares
CY2016Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	10000000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	23000	USD
CY2017Q4	us-gaap	Customer Deposits Noncurrent CustomerDepositsNoncurrent	12000	USD
CY2018Q2	us-gaap	Customer Deposits Noncurrent CustomerDepositsNoncurrent	12000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	135000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	98000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	46000	USD
CY2018Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	16000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12000	USD
CY2018Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	77000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23000	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	694000	USD
CY2018Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2017	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	12317000	USD
CY2017Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.02
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	1.23
CY2018Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.00
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.00
CY2018Q2	us-gaap	Disposal Group Including Discontinued Operation Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent	20000	USD
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	12709000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.69
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-716000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	292000	USD
CY2018Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-222000	USD
CY2018Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-222000	USD
CY2017Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-422000	USD
CY2018Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1602000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3043000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2075000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4210000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1722000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5141000	USD
	us-gaap	Interest Paid InterestPaid	92000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2253000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4524000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.15
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.54
CY2018Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.10
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.23
CY2017Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	248000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	11740000	USD
CY2018Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-24000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-24000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-547000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	996000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-478000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-294000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	43000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-489000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-14000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-16000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-23000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	145000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	33000	USD
CY2017Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-92000	USD
CY2018Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2017Q4	us-gaap	Liabilities Liabilities	2335000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	1938000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6706000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7222000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1583000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1903000	USD
CY2017Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2018Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	21000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	11636000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-3000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1051000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4373000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4851000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10600000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3865000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-1474000	USD
	us-gaap	Net Income Loss NetIncomeLoss	6599000	USD
	us-gaap	Operating Expenses OperatingExpenses	4309000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1275000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-2277000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4548000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	719000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-832000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-16000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	65000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	2441000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	2237000	USD
	us-gaap	Operating Expenses OperatingExpenses	4589000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2441000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4309000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2237000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4589000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	54000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	36000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	58000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	35000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2017Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	0	USD
CY2018Q2	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	7000	USD
CY2016Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	400000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	788000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	452000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	261000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	294000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6866000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3550000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2200000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7800000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56000	USD
CY2017Q2	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
CY2018Q1	us-gaap	Recapitalization Costs RecapitalizationCosts	141000	USD
CY2018Q2	us-gaap	Recapitalization Costs RecapitalizationCosts	17000	USD
	us-gaap	Recapitalization Costs RecapitalizationCosts	158000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7129000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	839000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1266000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	162000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	379000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-315987000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-320535000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	572000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	556000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0229
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0227
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1041000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	533000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	3905000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7084000	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	9415000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	700000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	695000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.66
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	369000	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1064000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.37
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.40
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.11
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	1275000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	4371000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	5284000	USD
CY2017Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	800000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11335000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9547000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23362000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19648000	shares

Files In Submission

Name	View Source	Status
0001017491-18-000075-index-headers.html	Edgar Link	pending
0001017491-18-000075-index.html	Edgar Link	pending
0001017491-18-000075.txt	Edgar Link	pending
0001017491-18-000075-xbrl.zip	Edgar Link	pending
apri-20180630.xml	Edgar Link	completed
apri-20180630.xsd	Edgar Link	pending
apri-20180630_cal.xml	Edgar Link	unprocessable
apri-20180630_def.xml	Edgar Link	unprocessable
apri-20180630_lab.xml	Edgar Link	unprocessable
apri-20180630_pre.xml	Edgar Link	unprocessable
apri6301810q.htm	Edgar Link	pending
apri63018ex311.htm	Edgar Link	pending
apri63018ex312.htm	Edgar Link	pending
apri63018ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEEL
Seelos Therapeutics Inc Stock $seel

2018 Q3 Form 10-Q Financial Statement

#000101749118000075 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL Seelos Therapeutics Inc Stock $seel

2018 Q3 Form 10-Q Financial Statement

#000101749118000075 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL
Seelos Therapeutics Inc Stock $seel